ARCH Venture Partners VIII, LLC

This profile gathers the share dealings of ARCH Venture Partners VIII, LLC across 2 companies, led by Sienna Biopharmaceuticals, Inc. and Twist Bioscience Corp. In total, 14 filings cover trades dated from 1 August 2017 to 22 February 2019.

Every open-market trade on record is a purchase: 5 purchases worth €5.7M, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2019: 3 purchases and no sales on the market.

A typical purchase (the median) is worth €331k. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

The newest entry dates from 26 February 2019: an open-market purchase of €4.1M, in Sienna Biopharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.